DCIS is a non-invasive breast cancer in milk ducts, but behavior varies widely, leaving doctors to decide which patients truly benefit from added radiation.
The biomarker test adds tumor biology to standard factors, estimating both recurrence risk and whether radiation is likely to change that risk.
Supporters say that matters because the tool can guide treatment both ways, helping some women skip radiation while identifying others who may benefit.
The proposed federal coverage policy questioned whether current biomarker tests add enough beyond existing clinical tools to justify payment under the national insurance system.
Federal agencies recognized innovation, yet lab tests remain outside a new accelerated coverage pathway; another national advisory panel is set for October 13.
US Debate Over Breast Test Coverage | Seguros de Propiedad, Accidentes, Salud y Vida

Leave a Reply